WO2002080918A1 - Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire - Google Patents

Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire Download PDF

Info

Publication number
WO2002080918A1
WO2002080918A1 PCT/JP2002/003295 JP0203295W WO02080918A1 WO 2002080918 A1 WO2002080918 A1 WO 2002080918A1 JP 0203295 W JP0203295 W JP 0203295W WO 02080918 A1 WO02080918 A1 WO 02080918A1
Authority
WO
WIPO (PCT)
Prior art keywords
represents hydrogen
urinary incontinence
hydrogen
frequent urination
remedial
Prior art date
Application number
PCT/JP2002/003295
Other languages
English (en)
Japanese (ja)
Inventor
Toshiaki Tanaka
Kuniaki Kawamura
Morihiro Fujimura
Toshikazu Komagata
Jun Miyakawa
Ko Hasebe
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of WO2002080918A1 publication Critical patent/WO2002080918A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

l'invention concerne un nouveau remède préventif en cas de miction fréquente ou d'incontinence urinaire qui comporte peu d'effets secondaires. Ce remède préventif en cas de miction fréquente ou d'incontinence urinaire contient en tant qu'ingrédient actif un dérivé de morphine substitué en position 6 représenté par la formule générale (I) ou son sel d'addition acide pharmaceutiquement acceptable. [Dans la formule (I), R1 représente hydrogène, etc. ; R2 et R3 représentent chacun hydrogène, etc. ; A représente NR4-(R4 étant hydrogène, etc.), -S-, ou O- ; R5 représente un groupe organique facultativement substitué dont le squelette de base est représenté par n'importe quelle formule (1) : (R10 étant hydrogène, etc.) ; R6 représente hydrogène et R7 représente hydrogène, etc. ; ou R6 et R7 combinés représentent -O-, etc. ; et R8 représente hydrogène, etc.]. Un exemple du dérivé est 17-(2-(2-thiophényl)éthyl)-4, 5α-époxy-3, 14β-dihydroxy-6β-(N-méthylanilino) méthanesulfonate de morphine.
PCT/JP2002/003295 2001-04-02 2002-04-02 Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire WO2002080918A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-103109 2001-04-02
JP2001103109 2001-04-02

Publications (1)

Publication Number Publication Date
WO2002080918A1 true WO2002080918A1 (fr) 2002-10-17

Family

ID=18956218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003295 WO2002080918A1 (fr) 2001-04-02 2002-04-02 Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire

Country Status (1)

Country Link
WO (1) WO2002080918A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033457A1 (fr) * 2002-10-09 2004-04-22 Toray Industries, Inc. Remedes ou produits preventifs pour la frequence urinaire ou l'incontinence urinaire, et derives de morphinane presentant un groupe heterocylique contenant de l'azote
EP1758452A1 (fr) * 2004-05-28 2007-03-07 Human Biomolecular Research Institute Synthèse d'analgésiques à métabolisme stable, de médicaments contre la douleur et d'autres agents
JP2011512360A (ja) * 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
JP2013534208A (ja) * 2010-07-16 2013-09-02 マリンクロッド エルエルシー トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用
JP2015535260A (ja) * 2012-10-30 2015-12-10 ネクター セラピューティクス オピオイド作動薬としてのα−６−ＭＰＥＧ６−Ｏ−ヒドロキシコドンの固体塩およびその使用
US10363251B2 (en) 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03218379A (ja) * 1989-11-13 1991-09-25 Chugai Pharmaceut Co Ltd 新規なモルヒネ誘導体
WO1993015081A1 (fr) * 1992-01-23 1993-08-05 Toray Industries, Inc. Derive de morphinane et utilisation en medicine
WO1995001178A1 (fr) * 1993-06-30 1995-01-12 Toray Industries, Inc. Antitussif
WO1995003308A1 (fr) * 1993-07-23 1995-02-02 Toray Industries, Inc. Derive de morphinane et application medicale
WO1996022276A1 (fr) * 1995-01-20 1996-07-25 Nippon Shinyaku Co., Ltd. Derives d'ethylamine et medicaments
JPH09501156A (ja) * 1993-07-30 1997-02-04 ザ．ウェルカム．ファウンデーション．リミテッド 治療法で使用するピペラジン化合物
JPH0977771A (ja) * 1995-09-14 1997-03-25 Toray Ind Inc イミニウム塩の製法
DE19602960A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999044065A1 (fr) * 1998-02-26 1999-09-02 University Of Strathclyde Techniques de dosage immunologique mettant en application une diffusion raman augmentee en surface

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03218379A (ja) * 1989-11-13 1991-09-25 Chugai Pharmaceut Co Ltd 新規なモルヒネ誘導体
WO1993015081A1 (fr) * 1992-01-23 1993-08-05 Toray Industries, Inc. Derive de morphinane et utilisation en medicine
WO1995001178A1 (fr) * 1993-06-30 1995-01-12 Toray Industries, Inc. Antitussif
WO1995003308A1 (fr) * 1993-07-23 1995-02-02 Toray Industries, Inc. Derive de morphinane et application medicale
JPH09501156A (ja) * 1993-07-30 1997-02-04 ザ．ウェルカム．ファウンデーション．リミテッド 治療法で使用するピペラジン化合物
WO1996022276A1 (fr) * 1995-01-20 1996-07-25 Nippon Shinyaku Co., Ltd. Derives d'ethylamine et medicaments
JPH0977771A (ja) * 1995-09-14 1997-03-25 Toray Ind Inc イミニウム塩の製法
DE19602960A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19602959A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2000505066A (ja) * 1995-12-20 2000-04-25 ニコムド イメージング エイエス 鎮痛活性を有するモルヒネ誘導体
WO1999044065A1 (fr) * 1998-02-26 1999-09-02 University Of Strathclyde Techniques de dosage immunologique mettant en application une diffusion raman augmentee en surface

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. DRAY ET AL.: "Inhibition of urinary bladder contractions by a spinal action of morphine and other opioids", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 231, no. 2, 1984, pages 254 - 260, XP002952992 *
A. DRAY ET AL.: "Morphine and the centrally-mediated inhibition of urinary bladder motility in the rat", BRAIN RESEARCH, vol. 297, no. 1, 1984, pages 191 - 195, XP002952993 *
A. DRAY ET AL.: "Opioids and central inhibition of urinary bladder motility", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 98, 1984, pages 155 - 156, XP002952995 *
MAXSON LIU ET AL.: "The synthesis of some 6,7-annulated codeines", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY, no. 3, 1999, pages 241 - 244, XP002952989 *
P.S. PORTOGHESE ET AL.: "Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety", J. MED. CHEMICAL, vol. 37, no. 5, 1994, pages 579 - 585, XP002952991 *
WOLFGANG BRANDT: "A uniform molecular model of delta opioid agonist and antagonist pharmacophore conformations", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, vol. 12, no. 6, 1998, pages 615 - 621, XP002952990 *
YASUHIKO IGAWA ET AL.: "Effects of morphine metabolites on micturition in normal, unanaesthetized rats", BR. J. PHARMACOL., vol. 110, no. 1, 1993, pages 257 - 262, XP002952994 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033457A1 (fr) * 2002-10-09 2004-04-22 Toray Industries, Inc. Remedes ou produits preventifs pour la frequence urinaire ou l'incontinence urinaire, et derives de morphinane presentant un groupe heterocylique contenant de l'azote
US7320984B2 (en) 2002-10-09 2008-01-22 Toray Industries, Inc. Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group
EP1758452A1 (fr) * 2004-05-28 2007-03-07 Human Biomolecular Research Institute Synthèse d'analgésiques à métabolisme stable, de médicaments contre la douleur et d'autres agents
EP1758452A4 (fr) * 2004-05-28 2009-08-05 Human Biomolecular Res Inst Synthèse d'analgésiques à métabolisme stable, de médicaments contre la douleur et d'autres agents
JP2011512360A (ja) * 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
US9040552B2 (en) 2008-02-14 2015-05-26 Alkermes, Inc. Selective opioid compounds
US9562014B2 (en) 2009-07-16 2017-02-07 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US10363251B2 (en) 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US10604488B2 (en) 2009-07-16 2020-03-31 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US11142502B2 (en) 2009-07-16 2021-10-12 Mallinckrodt Llc (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof
JP2013534208A (ja) * 2010-07-16 2013-09-02 マリンクロッド エルエルシー トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用
JP2015535260A (ja) * 2012-10-30 2015-12-10 ネクター セラピューティクス オピオイド作動薬としてのα−６−ＭＰＥＧ６−Ｏ−ヒドロキシコドンの固体塩およびその使用

Similar Documents

Publication Publication Date Title
GB0007405D0 (en) Compounds
CO5031285A1 (es) Triarilimidazoles
EP1548008A4 (fr) Compose presentant une activite inhibitrice du facteur de croissance transformant beta et composition medicamenteuse en contenant
EP1553084A4 (fr) Derive piperidine, procede de production, et utilisation
HK1046639A1 (en) Nitroimidazole external preparations for dermatosis
TW200635930A (en) Bicyclic pyrrole derivatives
HK1025572A1 (en) Tricyclic compounds
EP1813270A4 (fr) Inhibiteurs des proteines de la famille hsp90
WO2001094345A3 (fr) Composes chimiques
WO2003082855A1 (fr) Agent anti-inflammatoire
EP0686636A4 (fr) Derives tricycliques de benzazepine et benzothiazepine
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
EP1284272A4 (fr) Derives d'estra-1,3,5(10)-triene
EP1671957A4 (fr) Derives de thiadiazoline
WO2002080918A1 (fr) Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
WO2003028732A1 (fr) Antagoniste de recepteur
WO2003031414A1 (fr) Nouveau compose heterocyclique et agent anti-inflammatoire
CA2347506A1 (fr) Derives de quinazolinone
WO2007007905A3 (fr) Composes a base de carboxamide et son utilisation
EP1203771A4 (fr) Moyens de traitement et de prevention contre la miction frequente et l'incontinence d'urine
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
EP1211253A4 (fr) Derives dihydrobenzofuran tricycliques, leur procede de preparation et agents
EP1380299A4 (fr) Remedes de stimulation vesicale en association avec une hypertrophie de la prostate
EP1195377A4 (fr) Diesters d'acide maleique ou fumarique
WO2007007903A3 (fr) Compose de carboxamide et utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP